Literature DB >> 6114012

Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine.

M Ligumsky, F Karmeli, P Sharon, U Zor, F Cohen, D Rachmilewitz.   

Abstract

Accumulation of 6-ketoprostaglandin F1 alpha and thromboxane B2, the stable metabolites of prostacyclin I2 and thromboxane A2 respectively, by cultured rectal mucosa obtained from patients with active ulcerative colitis was significantly higher than their respective accumulation by cultured biopsy specimens obtained from normal subjects. Accumulation of prostacyclin I2 and thromboxane A2 by rectal mucosa obtained from ulcerative colitis patients in remission was not enhanced. Prostacyclin I2, thromboxane A2, and prostaglandin E2 accumulation was significantly inhibited by the addition to the culture medium of 5-aminosalicylic acid, flufenamic acid, aspirin, azathioprine, and methylprednisolone. Sulfapyridine inhibited significantly only prostaglandin E2 and prostacyclin I2 while sulfasalazine inhibited thromboxane A2, prostaglandin E2, and prostacyclin I2 accumulation. Flufenamic acid potentiated the inhibition of prostaglandin E2 accumulation induced by methylprednisolone when administered alone. These results suggest that in addition to the mediation by prostaglandin E2, thromboxane A2 and prostacylin I2 may also be involved in the inflammatory response in ulcerative colitis. Moreover, the therapeutic effects of steroid hormones and sulfasalazine may be partially related to their inhibition of colonic prostaglandin E2, prostacyclin I2, and thromboxane A2 synthesis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6114012

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  56 in total

1.  Temporal changes in colonic vascular architecture and inflammatory mediator levels in animal models of colitis.

Authors:  Caroline B Appleyard; Adrian Alvarez; William H Percy
Journal:  Dig Dis Sci       Date:  2002-09       Impact factor: 3.199

Review 2.  Sulfasalazine. Multiplicity of action.

Authors:  T S Gaginella; R E Walsh
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

Review 3.  The immunology of inflammatory bowel disease.

Authors:  J R Lowes; D P Jewell
Journal:  Springer Semin Immunopathol       Date:  1990

Review 4.  Inflammatory intermediaries in inflammatory bowel disease.

Authors:  K Lauritsen; L S Laursen; K Bukhave; J Rask-Madsen
Journal:  Int J Colorectal Dis       Date:  1989       Impact factor: 2.571

5.  Deposits of terminal complement complex (TCC) in muscularis mucosae and submucosal vessels in ulcerative colitis and Crohn's disease of the colon.

Authors:  T S Halstensen; T E Mollnes; O Fausa; P Brandtzaeg
Journal:  Gut       Date:  1989-03       Impact factor: 23.059

6.  Modulation of human colonic arachidonic acid metabolism by sulfasalazine.

Authors:  C J Hawkey; N K Boughton-Smith; B J Whittle
Journal:  Dig Dis Sci       Date:  1985-12       Impact factor: 3.199

7.  Inter-relationships between inflammatory mediators released from colonic mucosa in ulcerative colitis and their effects on colonic secretion.

Authors:  T D Wardle; L Hall; L A Turnberg
Journal:  Gut       Date:  1993-04       Impact factor: 23.059

8.  Ulcerative colitis: effect of sulphasalazine, its metabolites and indomethacin on the ability of human colonic mucosa to metabolize prostaglandins in vitro.

Authors:  K Hillier; P J Mason; S Pacheco; C L Smith
Journal:  Br J Pharmacol       Date:  1982-05       Impact factor: 8.739

9.  Dietary monounsaturated n-3 and n-6 long-chain polyunsaturated fatty acids affect cellular antioxidant defense system in rats with experimental ulcerative colitis induced by trinitrobenzene sulfonic acid.

Authors:  N Nieto; M I Fernandez; M I Torres; A Ríos; M D Suarez; A Gil
Journal:  Dig Dis Sci       Date:  1998-12       Impact factor: 3.199

10.  Incorporation of fatty acids from fish oil and olive oil into colonic mucosal lipids and effects upon eicosanoid synthesis in inflammatory bowel disease.

Authors:  K Hillier; R Jewell; L Dorrell; C L Smith
Journal:  Gut       Date:  1991-10       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.